A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT04196283 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors Cancer

Interventions

DRUG: ABBV-368
DRUG: Tilsotolimod
DRUG: Nab-paclitaxel
DRUG: ABBV-181

Sponsor

AbbVie

Collaborators

[object Object]